Thyroid cancer patients may spend less time in discomfort with simple phone calls

NCT ID NCT01298323

Completed Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults and compared those who received the outreach calls to those who did not. The goal was to see if early detection and management of side effects could improve the treatment experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vandetanib
What this could lead to: If successful, this outreach program could help patients on vandetanib spend less time dealing with bothersome side effects, improving their daily quality of life.
What could go wrong: This study focuses on managing side effects, not on curing cancer. The outreach program may not significantly reduce side effects, and results may not apply to other cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma medullary thyroid gland carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER MEDULLARY THYROID CANCER

Contacts and locations

Locations

Faculdade de Medicina de Ribeirao Preto - USP Site Number : 702

Ribeirão Preto, São Paulo, 14048-900, Brazil
Hospital De Clinicas De Porto Alegre Site Number : 701

Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
Investigational Site Number 1001

London, N6A 4L6, Canada
Investigational Site Number 1002

Sherbrooke, J1H 5N4, Canada
Investigational Site Number 1003

Toronto, M5G2M9, Canada
Investigational Site Number 1301

Beijing, 100021, China
Investigational Site Number 1302

Shanghai, China
Investigational Site Number 1901

Prague, 15006, Czechia
Investigational Site Number 2001

Odense C, 5000, Denmark
Investigational Site Number 2201

Helsinki, FI-00029, Finland
Investigational Site Number 2601

Würzburg, 97080, Germany
Investigational Site Number 2602

Essen, 45122, Germany
Investigational Site Number 2603

Halle, 06120, Germany
Investigational Site Number 2801

Sutton, SM25PT, United Kingdom
Investigational Site Number 2802

Glasgow, G120YN, United Kingdom
Investigational Site Number 3001

Athens, 11528, Greece
Investigational Site Number 301

St Leonards, 2065, Australia
Investigational Site Number 3501

Mumbai, 400012, India
Investigational Site Number 3502

Vellore, 632004, India
Investigational Site Number 4001

Jerusalem, 91120, Israel
Investigational Site Number 401

Vienna, 1901, Austria
Investigational Site Number 4101

Pisa, 56124, Italy
Investigational Site Number 4102

Roma, 00161, Italy
Investigational Site Number 4104

Naples, Italy
Investigational Site Number 501

Brussels, 1000, Belgium
Investigational Site Number 5702

Poznan, 60-355, Poland
Investigational Site Number 5703

Warsaw, 02-781, Poland
Investigational Site Number 6001

Seoul, South Korea
Investigational Site Number 6201

Moscow, 115478, Russia
Investigational Site Number 6202

Obninsk, 249036, Russia
Investigational Site Number 6203

Saint Petersburg, 197022, Russia
Investigational Site Number 6204

Moscow, 125284, Russia
Investigational Site Number 701

Porto Alegre, 90035-003, Brazil
Investigational Site Number 702

Ribeirão Preto, 14048-900, Brazil
Investigational Site Number 7201

Uppsala, 75185, Sweden
Investigational Site Number 901

Sofia, 1527, Bulgaria
Investigational Site Number : 1001

London, Ontario, N6A 4L6, Canada
Investigational Site Number : 1002

Sherbrooke, Quebec, J1H 5N4, Canada
Investigational Site Number : 1003

Toronto, Ontario, M5G2M9, Canada
Investigational Site Number : 1301

Beijing, 100021, China
Investigational Site Number : 1302

Shanghai, China
Investigational Site Number : 1901

Prague, 15006, Czechia
Investigational Site Number : 2001

Odense C, 5000, Denmark
Investigational Site Number : 2201

Helsinki, FI-00029, Finland
Investigational Site Number : 2601

Würzburg, 97080, Germany
Investigational Site Number : 2602

Essen, 45122, Germany
Investigational Site Number : 2603

Halle, 06120, Germany
Investigational Site Number : 2801

Sutton, Surrey, SM25PT, United Kingdom
Investigational Site Number : 2802

Glasgow, G120YN, United Kingdom
Investigational Site Number : 3001

Athens, 11528, Greece
Investigational Site Number : 301

St Leonards, New South Wales, 2065, Australia
Investigational Site Number : 3501

Mumbai, 400012, India
Investigational Site Number : 3502

Vellore, 632004, India
Investigational Site Number : 4001

Jerusalem, 91120, Israel
Investigational Site Number : 401

Vienna, 1901, Austria
Investigational Site Number : 4101

Pisa, 56124, Italy
Investigational Site Number : 4102

Roma, 00161, Italy
Investigational Site Number : 4104

Naples, Italy
Investigational Site Number : 501

Anderlecht, 1070, Belgium
Investigational Site Number : 5702

Poznan, Greater Poland Voivodeship, 60-355, Poland
Investigational Site Number : 5703

Warsaw, Masovian Voivodeship, 02-781, Poland
Investigational Site Number : 6001

Seoul, 03080, South Korea
Investigational Site Number : 6201

Moscow, 115478, Russia
Investigational Site Number : 6202

Obninsk, 249036, Russia
Investigational Site Number : 7201

Uppsala, 75185, Sweden
Investigational Site Number : 901

Sofia, 1527, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.